Sequential chemotherapy of cisplatin and vinorelbine followed by paclitaxel and gemcitabine in advanced non-small-cell lung cancer: A single institution phase II study

摘要: Abstract Background: To determine the activity and safety of a sequential regimen cisplatin vinorelbine followed by paclitaxel gemcitabine in patients with advanced non-small-cell lung cancer (NSCLC). Patients methods: Treatment was two cycles 80mg/m 2 on day 1 30mg/m days 8 every 3 weeks 175mg/m 1250mg/m 1and weeks. Results: Fifty-five inoperable NSCLC, performance status or less were enrolled, including 19 brain lesions. There 23 partial responses (42%; 95% confidence interval 29–55). The median time to progression overall survival 5.8 10.3 months, respectively (6.5 12.8 patient subset without metastases). One-year rate 47.5%. Grade III/IV neutropenia major side effect; it occurred 56% mainly limited first chemotherapy vinorelbine. Conclusions: Sequential combination is manageable active for NSCLC. It deserves be tested against standard two-drug scheme phase III trial.